Roswitha Kammler

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial

Viviana Galimberti, Bernard F. Cole, Giuseppe Viale et al. · The Lancet Oncology · 2018 · 533 citations

Surgical Oncology, Breast Oncology, Medicine +7

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial

Sherene Loi, Anita Giobbie‐Hurder, Andrea Gombos et al. · The Lancet Oncology · 2019 · 464 citations

Breast Oncology, Oncology, Pharmacology +8

CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

Meredith M. Regan, Brian Leyland‐Jones, Mark Bouzyk et al. · JNCI Journal of the National Cancer Institute · 2012 · 338 citations · Full text

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

Ann H. Partridge, Samuel M. Niman, Monica Ruggeri et al. · New England Journal of Medicine · 2023 · 202 citations · Full text

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

Rafael Rosell, Urania Dafni, Enriqueta Felip et al. · The Lancet Respiratory Medicine · 2017 · 182 citations

Medicine, Pathology, Immune Checkpoint Inhibitor +6